Ocular Hypotension
Hypotension
Hypotension, Controlled
Hypotension, Orthostatic
Intracranial Hypotension
Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. (1/48)
PURPOSE: Previous studies have shown that adenosine agonists are effective in reducing intraocular pressure (IOP). However, the mechanism(s) responsible for this ocular hypotensive effect has not been established. This study evaluates the relative contribution of changes in aqueous flow and outflow facility associated with the ocular hypotensive response to the adenosine agonist cyclohexyladenosine (CHA). METHODS: New Zealand White rabbits were treated topically in one eye with the adenosine A(1) agonist CHA. Changes in IOP, aqueous flow, and total outflow facility at various times after CHA administration were then determined. RESULTS: These studies demonstrated that CHA produces a dose-related reduction in IOP. Analysis of the dose-response curve revealed an ED(50) and a Hill coefficient of 87 microg and 1.9, respectively. Aqueous flow measurements demonstrated that 1.5 hours after CHA administration, aqueous flow was reduced by 35%. However, by 3.5 hours postdrug, no significant change in aqueous flow was observed. Measurement of the outflow facility found no significant change in facility 1.5 hours after CHA administration. However, by 3.5 hours after CHA administration, outflow facility was significantly increased by 85%. CONCLUSIONS: These data demonstrate that the adenosine agonist CHA lowers IOP in a dose-related fashion. This hypotensive action results from an early reduction in aqueous flow followed by a subsequent increase in outflow facility. This dual mechanism of action is consistent with analysis of CHA dose-response curve, which indicates that the reduction in IOP induced this agonist's results from multiple mechanisms of action. (+info)Clinical comparison of the Keeler Pulsair 3000 with Goldmann applanation tonometry. (2/48)
AIM: To confirm the accuracy of the Pulsair 3000 before introducing the instrument into clinical practice. METHOD: A masked study by two experienced tonometrists comparing the mean of the Goldmann intraocular pressure (IOP) readings against the Pulsair 3000 reading (average of four puffs). Results of 150 eyes were compared with an IOP range of 10 mm Hg-44 mm Hg. RESULTS: Correlation between the two Goldmann tonometry results was 0.9830 with a standard deviation of 1.1085 mm Hg. Correlation between the mean of the two Goldmann readings against the Pulsair 3000 reading was 0.982 with a standard deviation of 1.1179 mm Hg. Bland-Altman analysis confirms a satisfactory outcome. CONCLUSION: The Pulsair 3000 provides an accurate and objective method of measuring IOP with many advantages over traditional Goldmann tonometry. (+info)The National Survey of Trabeculectomy. III. Early and late complications. (3/48)
PURPOSE: There is a considerable body of literature relating to trabeculectomy, however there are no data representative of the national experience of trabeculectomy in the United Kingdom (UK). The Department of Health funded a national survey of trabeculectomy to establish current practice patterns and the outcome of trabeculectomy in the National Health Service (NHS). In this paper we present the reported complications of first-time trabeculectomy from a nationally representative cohort of patients with chronic open angle glaucoma. METHODS: Cross-sectional study of consultant ophthalmologists performing trabeculectomy in the NHS. Participants recruited their four most recent consecutive first-time trabeculectomy cases with chronic open angle glaucoma according to study eligibility criteria and data were collected by self-administered questionnaire. FOLLOW-UP: one year post-trabeculectomy. MAIN OUTCOME MEASURES: occurrence of early and late complications. RESULTS: Clinical outcome data were available for 1240 (85.3%) of cases. Early complications were reported in 578 (46.6%) cases and late complications in 512 (42.3%) cases. Some cases had more than one complication. The most frequent early complications were hyphaema (n = 304, 24.6%), shallow anterior chamber (n = 296, 23.9%), hypotony (n = 296, 24.3%), wound leak (n = 216, 17.8%) and choroidal detachment (n = 175, 14.1%). The most frequent late complications were cataract (n = 251, 20.2%), visual loss (n = 230, 18.8%) and encapsulated bleb (n = 42, 3.4%). The occurrence of most complications was not associated with a consultant's specialist interest, level of activity, type of hospital or region. Encapsulated bleb was reported more frequently in a university hospital setting. CONCLUSIONS: The complication rates reported in this paper represent the national experience of first-time trabeculectomy for open angle glaucoma in the UK. These are similar to previous published studies and highlight in particular, the impact of trabeculectomy on visual acuity in the first year following surgery. This survey provides valid and clinically relevant data on the complications of trabeculectomy for the production of guidelines and standards for audit at regional, local and individual level. (+info)Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites. (4/48)
In a previous study we ascertained the presence of sigma1 and sigma2 recognition sites in the rabbit iris-ciliary body, an ocular structure involved in aqueous humor production and drainage. We characterized the sigma1 sites using the preferential ligand (+)-pentazocine, which caused a significant reduction of intraocular pressure (IOP). In the present study, flunarizine, a calcium channel blocker with a complex pharmacological profile, bound to sigma1 sites expressed in the iris-ciliary body with moderate affinity (K(i) = 68 nM). Unilateral topical flunarizine (0.01-0.1%) caused a dose-related reduction of IOP in ocular normotensive rabbits and in the alpha-chymotrypsin model of ocular hypertension, without altering the IOP of the contralateral eye. This activity was blocked by the sigma1 site antagonist NE-100 [N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine HCl] which, by itself, had no effect on IOP. Detection of flunarizine in rabbit iris-ciliary body homogenates, after topical instillation, showed that it adequately penetrates the rabbit eye. To investigate mechanisms that may contribute to ocular hypotension induced by sigma1 agonists, we carried out in vitro studies on the isolated rabbit iris-ciliary body. Flunarizine (IC50 = 5. 96 nM) and (+)-pentazocine (IC50 = 3. 81 nM) inhibited [3H]norepinephrine release. Moreover, flunarizine (IC50 = 6.34 nM) and (+)-pentazocine (IC50 = 27.26 nM) also antagonized isoproterenol-induced cAMP accumulation. The action of flunarizine and (+)-pentazocine was sensitive to NE-100 antagonism; however, this latter compound partially prevented their effect on [3H]norepinephrine and cAMP accumulation. These findings indicate that flunarizine and (+)-pentazocine interact with ocular sigma1 sites and may prove effective in the control of ocular hypertension. (+info)Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. (5/48)
(1) Melatonin is involved in the control of intraocular pressure during the night and day photoperiod. We have investigated the receptor that regulates intraocular pressure in New Zealand white rabbits by means of agonists and antagonists of melatonin receptors. (2) Melatonin and its analogues: 2-Phe-melatonin, 6-Cl-melatonin, 2-I-melatonin, 5- methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) and N-acetyltryptamine all produced a reduction in intraocular pressure. Dose-response analysis for these compounds gave pD(2) values of 9.3+/-0.24 for melatonin; 9.0+/-0.09 for 6-Cl-melatonin; 9.0+/-0.84 for 2-I-melatonin; 8.9+/-0.07 for 5-MCA-NAT; 8.7+/-0.18 for 2-Phe-melatonin and 9.4+/-0.30 for N-acetyltryptamine (all n=8). (3) At a dose of 0.5 nmol (in 10 micro l) melatonin and the selective melatonin MT(3) agonist 5-MCA-NAT, induced greater reductions of intraocular pressure (22.8+/-2.3% and 32.5+/-1.4%, respectively) than the other compounds. (4) The melatonin-receptor antagonists, prazosin, DH-97 and 4-P-PDOT, reversed the effect of 5-MCA-NAT in a dose-dependent manner, with pA(2) values of 13.5+/-0.17 for prazosin, 10.6+/-0.16 for DH-97 and 9.4+/-0.20 for 4-P-PDOT (n=8). (5) Cholinoceptor antagonists (hexamethonium and atropine) and alpha(2)- and beta(2)-adrenoceptor antagonists (yohimbine and ICI 118,551) partially reversed the effects produced by melatonin and 5-MCA-NAT, suggesting the possible involvement of cholinergic and noradrenergic systems in the hypotensive actions mediated by melatonin agonists. The alpha(1)-adrenoceptor antagonist, corynanthine, had no significant effect. (6) The strong hypotensive effect of the MT(3) agonist, 5-MCA-NAT, suggests that this compound may be a useful agent for treating those pathologies where intraocular pressure is abnormally elevated. (+info)Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. (6/48)
This study covered the ocular hypotensive effects of the stereoisomers of the alpha 2-adrenoceptor agonist medetomidine. The dextro-isomer, dexmedetomidine, is known from pharmacologic experiments to be a specific, potent, and selective full agonist at alpha 2-adrenoceptors, whereas the levo-enantiomer seems to be almost inactive. Thus, the levo-isomer (0.5 mg/ml, 25 microliters) had no significant effect on intraocular pressure. After unilateral topical administration, dexmedetomidine (0.5 mg/ml, 25 microliters) lowered intraocular pressure bilaterally in normal rabbits and in rabbits with intraocular pressure elevated after laser irradiation of the pigmented trabecular band of the anterior chamber angle. In the treated (ipsilateral) eye of normal rabbits, a maximum decrease of 4.6 +/- 0.6 mmHg was observed at 2 hr post treatment. In the contralateral eye, the maximum decrease was 4.1 +/- 0.5 mmHg at 1 hr after treatment. In rabbits with laser-induced elevation of intraocular pressure, the maximum decrease in treated hypertensive eyes was 13.5 +/- 0.3 mmHg 1 hr after dexmedetomidine administration. These results indicate that the selective alpha 2-adrenoceptor agonist, dexmedetomidine, is a potent and effective drug for decreasing intraocular pressure in rabbits. (+info)Outcomes of bleb excision and conjunctival advancement for leaking or hypotonous eyes after glaucoma filtering surgery. (7/48)
AIM: To determine outcomes of bleb excision and conjunctival advancement for leaking or hypotonous eyes after glaucoma filtering surgery. METHODS: In a retrospective case series the medical records of all patients who underwent bleb excision and conjunctival advancement surgery for bleb leaks or hypotony (defined as IOP less than 6 mm Hg, associated with reduced vision) at the Jules Stein Eye Institute and the Yale University Eye Center between January 1993 and June 2002 were reviewed. Only patients with more than 6 months of follow up were included. Complete success was defined as resolution of the pre-existing leak or hypotony, with maintenance of IOP > or =6 and < or =21 mm Hg, in the absence of further glaucoma surgery and without any glaucoma medication. Qualified success met the above criteria with or without the use of glaucoma medications. Success rates were analysed with Kaplan-Meier survival curves. RESULTS: 49 eyes were included in the study; 13 eyes had overt bleb leaks, 27 eyes had hypotony. Nineteen patients underwent resuturing of sclera and/or placement of a pericardial graft in addition to bleb excision and conjunctival advancement. Mean preoperative IOP increased from 3.2 (SD 2.4) mm Hg (range 0-10 mm Hg) to 13.8 (4.8) mm Hg (range 6-29 mm Hg) at last follow up (p<0.0001). Mean preoperative visual acuity improved from 0.6 (0.3) logMAR (range 0-2) to 0.3 (0.3) logMAR (range 0-2) at final follow up (p<0.0001). 16 eyes (40%) were classified as complete success and 17 additional eyes achieved qualified success, for a total of 33 eyes (83%) achieving at least qualified success. There was no significant difference in the rate of complete success (p = 0.95) or qualified success (p = 0.88) between the group of patients who underwent bleb excision and conjunctival advancement alone versus those who also had resuturing of sclera and/or placement of a pericardial graft. Failures included three eyes that had persistent hypotony without leak, requiring additional bleb revision, and four with uncontrolled IOP, two of whom underwent additional glaucoma surgery. CONCLUSION: Bleb excision with conjunctival advancement is a successful procedure for bleb repair. This technique provides successful resolution of leaks and hypotony, maintains glaucoma control with or without medication, and preserves vision with minimal postoperative complications in a majority of eyes. (+info)Management of hypotony after trabeculectomy with mitomycin C. (8/48)
The purpose of this study was to determine the incidence and risk factors of hypotony and the effectiveness of medical and surgical treatment. A total 117 eyes of 103 patients that underwent trabeculectomy with mitimycin C (MMC) between 1993 and 2000 were reviewed. Hypotony was treated with the following methods in a stepwise manner: medical treatment, intrableb autologous blood injection, additional sutures to the scleral flap, necrotic bleb excision and advancement of the forniceal conjunctival flap. Hypotony developed in 30 eyes (25.6%) of 26 patients, among, which hypotonic maculopathy developed in 11 eyes (9.4%). The risk factors of hypotony were young age and primary open angle glaucoma. Because of no light sense, 6 of the 30 hypotonic eyes were not treated. Nineteen (79.2%) of the 24 treated hypotonic eyes were successfully managed. Five eyes, 3 with hypotony but maintaining visual acuity and 2 with follow-up loss, were not included in the success group. The mean intraocular pressure (IOP) before treatment, 2.5 +/- 1.2 mmHg, increased to 8.3 +/- 4.0 mmHg at 18.5 months follow-up. The stepwise treatment seems to be a useful method to manage hypotony after trabeculectomy with MMC. (+info)Ocular hypotension is a medical term that refers to a condition where the pressure inside the eye (intraocular pressure or IOP) is lower than normal. The normal range for IOP is typically between 10-21 mmHg (millimeters of mercury). Ocular hypotension can occur due to various reasons, including certain medications, medical conditions, or surgical procedures that affect the eye's ability to produce or drain aqueous humor, the clear fluid inside the eye.
While mild ocular hypotension may not cause any symptoms, more significant cases can lead to complications such as decreased vision, optic nerve damage, and visual field loss. If left untreated, it could potentially result in a condition called glaucoma. It is essential to consult an eye care professional if you suspect ocular hypotension or experience any changes in your vision.
Intraocular pressure (IOP) is the fluid pressure within the eye, specifically within the anterior chamber, which is the space between the cornea and the iris. It is measured in millimeters of mercury (mmHg). The aqueous humor, a clear fluid that fills the anterior chamber, is constantly produced and drained, maintaining a balance that determines the IOP. Normal IOP ranges from 10-21 mmHg, with average values around 15-16 mmHg. Elevated IOP is a key risk factor for glaucoma, a group of eye conditions that can lead to optic nerve damage and vision loss if not treated promptly and effectively. Regular monitoring of IOP is essential in diagnosing and managing glaucoma and other ocular health issues.
Hypotension is a medical term that refers to abnormally low blood pressure, usually defined as a systolic blood pressure less than 90 millimeters of mercury (mm Hg) or a diastolic blood pressure less than 60 mm Hg. Blood pressure is the force exerted by the blood against the walls of the blood vessels as the heart pumps blood.
Hypotension can cause symptoms such as dizziness, lightheadedness, weakness, and fainting, especially when standing up suddenly. In severe cases, hypotension can lead to shock, which is a life-threatening condition characterized by multiple organ failure due to inadequate blood flow.
Hypotension can be caused by various factors, including certain medications, medical conditions such as heart disease, endocrine disorders, and dehydration. It is important to seek medical attention if you experience symptoms of hypotension, as it can indicate an underlying health issue that requires treatment.
Controlled hypotension is a medical procedure in which the healthcare provider intentionally lowers the patient's blood pressure during surgery. This is done to reduce bleeding and improve surgical conditions. The goal is to maintain the patient's blood pressure at a level that is lower than their normal resting blood pressure, but high enough to ensure adequate blood flow to vital organs such as the heart and brain. Controlled hypotension is closely monitored and managed throughout the surgery to minimize risks and ensure the best possible outcomes for the patient.
Orthostatic hypotension is a type of low blood pressure that occurs when you stand up from a sitting or lying position. The drop in blood pressure causes a brief period of lightheadedness or dizziness, and can even cause fainting in some cases. This condition is also known as postural hypotension.
Orthostatic hypotension is caused by a rapid decrease in blood pressure when you stand up, which reduces the amount of blood that reaches your brain. Normally, when you stand up, your body compensates for this by increasing your heart rate and constricting blood vessels to maintain blood pressure. However, if these mechanisms fail or are impaired, orthostatic hypotension can occur.
Orthostatic hypotension is more common in older adults, but it can also affect younger people who have certain medical conditions or take certain medications. Some of the risk factors for orthostatic hypotension include dehydration, prolonged bed rest, pregnancy, diabetes, heart disease, Parkinson's disease, and certain neurological disorders.
If you experience symptoms of orthostatic hypotension, it is important to seek medical attention. Your healthcare provider can perform tests to determine the underlying cause of your symptoms and recommend appropriate treatment options. Treatment may include lifestyle changes, such as increasing fluid intake, avoiding alcohol and caffeine, and gradually changing positions from lying down or sitting to standing up. In some cases, medication may be necessary to manage orthostatic hypotension.
Intracranial hypotension is a medical condition characterized by reduced pressure within the cranial cavity (the space containing brain and cerebrospinal fluid). This can occur due to several reasons, most commonly being a spontaneous or traumatic CSF leak (cerebrospinal fluid leak) from the dural membrane that surrounds the brain and spinal cord. The decrease in CSF pressure can cause various symptoms such as headaches (often positional), nausea, vomiting, neck pain, blurred vision, ringing in the ears, and cognitive impairment. Treatment typically involves identifying and addressing the underlying cause, which may include bed rest, hydration, caffeine, epidural blood patch procedures, or surgical repair of CSF leaks.
Buphenine
Anesthesia for eye surgery
Sohan Hayreh
RKI-1447
AL-34662
Medical cannabis
Intraocular pressure
Ocular hypotony
Crotalus durissus
Ergoloid
Tityus stigmurus
Anterior chamber paracentesis
List of dangerous snakes
Betaxolol
Visual impairment due to intracranial pressure
Wernicke encephalopathy
Ophthalmic artery
Poly(methyl methacrylate)
O-1918
Dexamethasone
Wernicke-Korsakoff syndrome
Effect of spaceflight on the human body
Retinopathy of prematurity
Ophthalmic drug administration
Marburg virus disease
Acetazolamide
Signs and symptoms of Parkinson's disease
Lewisite 3
Lewisite 2
Glaucoma
Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension
Buphenine - Wikipedia
Bufenin - Wikipedija / Википедија
Case Definitions for Chemical Poisoning
Ciliary Body Melanoma: Overview, Pathophysiology, Etiology
Ocular Manifestations of Leprosy: Overview, Clinical Presentation, Diagnosis
DailyMed - DEFEROXAMINE MESYLATE injection, powder, lyophilized, for solution
Ciliary Body Melanoma: Overview, Pathophysiology, Etiology
Ocular Hypotensive Effect of Oral Palmitoyl-ethanolamide: A Clinical Trial | IOVS | ARVO Journals
CDC | Case Definition: Trichothecene Mycotoxin Poisoning
DailyMed - DESFLURANE liquid
Ocular Perfusion Pressure in Spaceflight-Associated Neuro-Ocular Syndrome
Hypertension-Hypotension. Blood Pressure Measurements in Dogs And Cats - WSAVA2002 - VIN
Comparison of Newly Diagnosed Ocular Hypertension and Open-Angle Glaucoma: Ocular Variables, Risk Factors, and Disease Severity
Carteolol Hydrochloride Ophthalmic Solution USP, 1% (Bausch & Lomb), Drug Reference Encyclopedia
MedlinePlus: Genetic Conditions: H
Arsine | Medical Management Guidelines | Toxic Substance Portal | ATSDR
Frontiers | Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain
CDC | Case Definition: Trichothecene Mycotoxin Poisoning
Introduction and Advanced Critical Care Ultrasound
Introduction to Emergency Medicine Ultrasound
MeSH Browser
Miochol E, (acetylcholine) dosing, indications, interactions, adverse effects, and more
Opthamology Data (1971-75)
Thiabendazole sources, health risks
Normal Tension Glaucoma - StatPearls - NCBI Bookshelf
Combivent (Ipratropium Bromide and Albuterol Sulfate): Uses, Dosage, Side Effects, Interactions, Warning
DeCS 2019 - June 12, 2019 version
A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and...
Systemic10
- There are well-known associations between systemic arterial hypertension and a variety of ocular disorders that were previously considered to be primarily manifestations of arterial hypertension. (nih.gov)
- These studies suggest that several of the ocular or optic nerve head ischemic or ocular vascular disorders previously thought to be manifestations of arterial hypertension may, in fact, be due to a combination of systemic arterial hypertension and hypotension, with arterial hypertension acting as a predisposing factor and arterial hypotension actually producing the disorders. (nih.gov)
- Systemic administration of PEA reduces IOP in patients with glaucoma and ocular hypertension. (arvojournals.org)
- Systemic symptoms can develop with all routes of exposure (especially inhalation) and might include weakness, ataxia, hypotension, coagulopathy, and death (1). (cdc.gov)
- Understanding the mechanisms of these diseases as well as the relationship between IOP, eye size, gravity, ocular and systemic fluid dynamics, and ICP is vital to understand and develop ways to prevent, modulate, and treat SANS. (uwaterloo.ca)
- Timolol (systemic): Bradycardia, hypotension, bronchospasm and cardiac arrest. (azurewebsites.net)
- This case demonstrates that ocular exposure to xylazine can cause systemic central nervous system and cardiovascular effects. (indexindex.com)
- See Table 22-4 in BCSC Section 6, Pediatric Ophthalmology and Strabismus, for a comparison of systemic and ocular adverse effects of glaucoma medications in children. (aao.org)
- The systemic absorption of these agents is considerable-even with topical application-and can cause bronchospasm, bradycardia, and hypotension in susceptible children. (aao.org)
- A-AION is an ocular emergency and requires immediate treatment with systemic corticosteroids to prevent further visual loss. (intechopen.com)
Glaucoma9
- To investigate the effect of oral palmitoyl-ethanolamide (PEA) on intraocular pressure (IOP) in primary open angle glaucoma (POAG) and ocular hypertension (OH). (arvojournals.org)
- The impairment of ocular haemodynamics has been reported in primary open angle glaucoma (POAG) patients using various blood flow measurement techniques. (uwaterloo.ca)
- To describe the distribution of ocular variables, risk factors, and disease severity in newly diagnosed ocular hypertension (OH) or open-angle glaucoma (OAG). (hindawi.com)
- Presently, risk factors with strongest evidence for conversion of ocular hypertension (OH) to glaucoma, or presence and progression of open-angle glaucoma (OAG), include older age, thinner central corneal thickness (CCT), greater cup-to-disc ratio (C/D ratio), and higher intraocular pressure (IOP). (hindawi.com)
- The ocular hypotensive effects of cannabinoids, specifically, have generated considerable interest over the last few decades largely due to their potential use in the treatment of glaucoma. (frontiersin.org)
- Aim To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension. (bmj.com)
- LBN exhibited potent and effective IOP-lowering activity in three ocular hypertensive glaucoma animal models. (bmj.com)
- As monotherapy or as adjunctive therapy to beta-blockers in the treatment of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults. (medscape.co.uk)
- Viral transduction of the mouse trabecular meshwork using a variety of transgenes associated with glaucoma generates an inducible and reproducible method for generating ocular hypertension due to increased aqueous humor outflow resistance of the conventional outflow pathway. (bvsalud.org)
Bradycardia5
- It can cause hypotension or low blood pressure, bradycardia or a heart rate of under 60 beats per minute. (naturalpedia.com)
- Timolol: May have additive effects resulting in hypotension and/or notable bradycardia with oral Ca channel blockers, guanethidine, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. (azurewebsites.net)
- The reported effects include hypotension, bradycardia, and respiratory depression. (indexindex.com)
- Two hours after the exposure, the patient developed sinus bradycardia (40-50 beats/min), hypotension (90/60 mm Hg), and a decreased level of consciousness. (indexindex.com)
- The patient was admitted for observation, during which the bradycardia and hypotension were noted to persist. (indexindex.com)
Hypotony3
- Within a week of onset of her first episode of acute anterior uveitis, a 45 year-old Caucasian lady developed profound ocular hypotony with unrecordable intraocular pressures, reduced vision and choroidal folds. (birmingham.ac.uk)
- abstract = "BackgroundWe report a case of a HLA-B27 negative patient presenting with severe, bilateral, idiopathic acute anterior uveitis with acute hypotony and hypotony maculopathy as their first uveitic episode.Case presentationWithin a week of onset of her first episode of acute anterior uveitis, a 45 year-old Caucasian lady developed profound ocular hypotony with unrecordable intraocular pressures, reduced vision and choroidal folds. (birmingham.ac.uk)
- When IOP is below 5 mmHg, this condition is known as ocular hypotony and needs to be corrected. (auto-oph.com)
Corneal2
- Chronologically, beading of the corneal nerves is probably the earliest detectable ocular finding (see image below). (medscape.com)
- This review will highlight evidence from experimental studies identifying components of the ocular ECS and discuss the functional role of the ECS during different ocular inflammatory disease states, including uveitis and corneal keratitis. (frontiersin.org)
Uveitis1
- In the Carville Public Health Service (PHS) Hospital, 16% of the first ocular lesions noticed were episcleritis, scleritis, or uveitis. (medscape.com)
Aqueous humor1
- Separation and disruption of the overlying ciliary epithelium decreases its production of aqueous humor with consequent ocular hypotension. (medscape.com)
Treatment of ocular1
- Candidate ECS targeted therapies will be discussed, drawing on experimental results obtained from both ocular and non-ocular tissue(s), together with their potential application for the treatment of ocular inflammation and pain. (frontiersin.org)
Hypotensive medications1
- With the development of potent arterial hypotensive medications for arterial hypertension, arterial hypotension (particularly nocturnal hypotension) is increasingly emerging as an important cause of visual disorders. (nih.gov)
Retinal1
- BACKGROUND: This study aims to investigate the protective effect of Toll-like receptor 4 (TLR4) inhibitor Resatorvid (TAK-242) on retinal ganglion cells (RGCs) in a chronic ocular hypertension (COH) rat model, as well as to explore the potential involved mechanisms. (bvsalud.org)
Inflammation2
- Of these diseases, ocular inflammation presents a significant medical problem, given that current clinical treatments can be ineffective or are associated with intolerable side-effects. (frontiersin.org)
- Furthermore, a prominent comorbidity of ocular inflammation is pain, including neuropathic pain, for which therapeutic options remain limited. (frontiersin.org)
Ophthalmic1
- The following information was collected on standardized data collection sheets: demographics, medical history, ocular family history, and complete ophthalmic examination including visual fields. (hindawi.com)
Conjunctival1
- Symptoms: Latanoprost: Ocular irritation and conjunctival hyperaemia. (azurewebsites.net)
Ultrasound1
- State an algorithm for uses of bedside ultrasound during cardiac arrest, sepsis, shock, and hypotension. (gcus.com)
Chronic1
- Hypotension may be observed in small animal patients in shock and hypovolemia, with Morbus Addison, in chronic heart failure, hypothyroidism and possibly of toxic and/or infectious origin. (vin.com)
Complications2
- These reports attribute ocular complications to the transient thrombocytopenia and resulting bleeding diathesis. (cdc.gov)
- Cardiac involvement is common , as are ocular or renal complications. (genosalut.com)
Adverse Effects1
- Visual Disturbances: Visual or ocular adverse effects may occur. (pfizermedicalinformation.com)
Renal1
- This technique should be used widely as a screening method for the pre-clinical detection of hypertension in patients with renal disease, hyperthyroidism, ocular changes consistent with hypertension, a cardiac murmur, left ventricular hypertrophy, neurological dysfunction and all cats over eight years of age. (vin.com)
Nocturnal1
- Recent studies with 24-hour ambulatory blood pressure monitoring have shown that the development and progression of nonarteric anterior ischemic optic neuropathy and glaucomatous optic neuropathy are significantly correlated with nocturnal arterial hypotension, particularly in hypertensive patients receiving oral hypertensive therapy. (nih.gov)
Latanoprost1
- 10-12 BOL-303259-X, also known as latanoprostene bunod (LBN), is a new IOP-lowering agent that, when exposed to ubiquitous esterases in the ocular environment, is cleaved into latanoprost acid, a prostaglandin F2α receptor agonist, and butanediol mononitrate, a nitric oxide (NO)-donating moiety. (bmj.com)
Disorders2
- Therefore, it is strongly recommended that when a patient is at risk for ocular or optic nerve head ischemic or ocular vascular disorders, the ophthalmologist should talk to the treating physician about the potential risks of intensive arterial hypotensive therapy, particularly that administered in the evening or at bedtime. (nih.gov)
- Autonomic features include postural hypotension and gastrointestinal and genitourinary disorders . (genosalut.com)
Toxicity1
- Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. (nih.gov)
Instillation1
- Carteolol has not been detected in plasma following ocular instillation. (theodora.com)
Symptoms1
- Discontinue use if visual or ocular symptoms occur. (pfizermedicalinformation.com)
Occur1
- Conclusions: Our findings show that OPP increases sufficient to compromise autoregulation do occur with change in body posture indicating a possible mechanism for the observed ocular changes that occur during spaceflight. (uwaterloo.ca)
Surgery1
- Exclusion criteria included subjects previously or currently receiving ocular hypotensive therapy, a history of ocular surgery (except cataract surgery), or ocular trauma. (hindawi.com)
Glaucomatous1
- In the present study, we investigated the role of SNHG11 in TM cells using immortalized human TM and glaucomatous human TM (GTM3 ) cells and an acute ocular hypertension mouse model. (bvsalud.org)
Receptor1
- Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe hypotension during anesthesia. (theodora.com)
Tissue1
- The ocular tissue where these tumors arise, the uvea, is a densely pigmented layer that lies for the most part between the sclera and the retina. (medscape.com)
Mortality2
- Association between postinduction hypotension and postoperative mortality: a single-centre retrospective cohort study. (qxmd.com)
- These drugs included hypotension include non-cause mortality, diabetes, orthostatic hypertrophy or high blood pressure. (occidentalia.net)
Beta-blockers1
- The exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated. (theodora.com)
Manifestations2
- Ocular therapy depends on the manifestations of the disease and may involve medical and surgical measures. (medscape.com)
- Since Mycobacterium leprae and Mycobacterium lepromatosis cannot survive at body temperature, their ocular manifestations mainly involve the ocular adnexa and the anterior part of the globe. (medscape.com)
Exposure1
- Ocular exposure might result in blurred vision, and inhalational exposure might cause nasal irritation and cough. (cdc.gov)
Significant1
- Purpose: Spaceflight associated neuro-ocular syndrome (SANS) is considered by the National Aeronautics and Space Administration (NASA) as one of the most significant barriers to long term space exploration (Larkin, 2018). (uwaterloo.ca)